Frank Tverdek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Frank Tverdek has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Catherine Liu
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington
4 shared publications - Julian Lindsay
Haematology Department, Royal North Shore Hospital, Sydney, Australia
2 shared publications Paul Hendrie
Division of Hematology and Oncology, Department of Medicine, University of Washington , Seattle, Washington
2 shared publications- Rupali Jain
School of Pharmacy, University of Washington, Seattle, WA, USA
2 shared publications Steven A. Pergam
Fred Hutchinson Canc Ctr, Infect Prevent Dept, Seattle, WA USA
2 shared publications- Allison Thibodeau
Fred Hutchinson Cancer Center
1 shared publication
Latest Publications
- Open Access
- 14 September 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (10)
Comparative Neurotoxicity of Polymyxin B and Colistin in Patients With Cancer
Background: The polymyxins, polymyxin B and colistin, are last‐line options for the treatment of infections caused by drug‐resistant gram‐negative organisms. The comparative neurotoxicity of these agents using contemporary dosing is poorly understood. We sought to compare the incidence of neurotoxicity among recipients of polymyxin B or colistin. Methods: This was a single‐center, retrospective cohort study of all patients who received colistin or polymyxin B for the treatment of a serious gram‐negative infection between March 2016 and April 2020. The primary outcome of interest was treatment‐emergent neurotoxicity, defined as new‐onset perioral paresthesia, non‐oral paresthesia, peripheral neuropathy, seizure, diaphragmatic paralysis, or other neurotoxicity. Bivariate analyses were performed using Fisher's exact test and the Wilcoxon rank‐sum test; no multivariable analyses were performed. Results: A total of 82 patients receiving polymyxin B ( n = 39) or colistin ( n = 43) were identified. Neurotoxicity, nearly exclusively paresthesia, was more commonly seen in recipients of polymyxin B (10/39 evaluable patients, 26%) versus colistin (1/42 evaluable patients, 2%; p < 0.01). Neurotoxicity most commonly developed on the first day of therapy and resolved with discontinuation of therapy or prolongation of the infusion duration. Conclusions: Polymyxin B is associated with significantly more neurotoxicity than colistin in unadjusted analyses. This potential risk should be considered when choosing between these two agents.
- 14 September 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (10)
Open AccessComparative Neurotoxicity of Polymyxin B and Colistin in Patients With Cancer
Background: The polymyxins, polymyxin B and colistin, are last‐line options for the treatment of infections caused by drug‐resistant gram‐negative organisms. The comparative neurotoxicity of these agents using contemporary dosing is poorly understood. We sought to compare the incidence of neurotoxicity among recipients of polymyxin B or colistin. Methods: This was a single‐center, retrospective cohort study of all patients who received colistin or polymyxin B for the treatment of a serious gram‐negative infection between March 2016 and April 2020. The primary outcome of interest was treatment‐emergent neurotoxicity, defined as new‐onset perioral paresthesia, non‐oral paresthesia, peripheral neuropathy, seizure, diaphragmatic paralysis, or other neurotoxicity. Bivariate analyses were performed using Fisher's exact test and the Wilcoxon rank‐sum test; no multivariable analyses were performed. Results: A total of 82 patients receiving polymyxin B ( n = 39) or colistin ( n = 43) were identified. Neurotoxicity, nearly exclusively paresthesia, was more commonly seen in recipients of polymyxin B (10/39 evaluable patients, 26%) versus colistin (1/42 evaluable patients, 2%; p < 0.01). Neurotoxicity most commonly developed on the first day of therapy and resolved with discontinuation of therapy or prolongation of the infusion duration. Conclusions: Polymyxin B is associated with significantly more neurotoxicity than colistin in unadjusted analyses. This potential risk should be considered when choosing between these two agents.
- Open Access
- 20 January 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (4) , e826-e834
Diagnostic Yield of Repeat Blood Cultures and Risk Factors for Bloodstream Infection in Persistent Febrile Neutropenia
Background: The optimal frequency of repeat blood cultures in persistent febrile neutropenia (FN) remains unknown. This study aimed to identify opportunities for blood culture diagnostic stewardship in persistent FN. Methods: This was a retrospective cohort study of patients with hematology/oncology diagnoses and an FN episode lasting >3 days. Generalized estimating equation logistic regression models were used to evaluate risk factors for new bloodstream infection (BSI) after FN day 3. Results: Among 620 patients, the median FN duration was 5 days, with a median of 12 blood culture bottles collected per patient. On FN day 1, 25% of patients had a positive blood culture; on FN days 2–9, <5% of patients per day had a new organism isolated. Among 31 new organisms isolated after FN day 3, 8 (26%) were contaminants. Of 503 patients with ≥1 blood culture collected after FN day 3, 19 (4%) had a new BSI after FN day 3. FN onset in the peri–hematopoietic cell transplant period (from day −7 to day +30) was associated with lower odds of new BSI after FN day 3 (odds ratio, 0.18 [95% confidence interval, .04–.71]; P = .01). Thirty-six patients died within 30 days after FN day 3, including 4 with a new BSI after FN day 3; 1 death was attributable to BSI after FN day 3. Conclusions: Detection of new BSIs after FN day 3 was uncommon, demonstrating the low diagnostic yield of repeat blood cultures after FN day 3. FN episodes in the peri–hematopoietic cell transplant period may be a potential focus for blood culture diagnostic stewardship initiatives.
- 20 January 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (4) , e826-e834
Open AccessDiagnostic Yield of Repeat Blood Cultures and Risk Factors for Bloodstream Infection in Persistent Febrile Neutropenia
Background: The optimal frequency of repeat blood cultures in persistent febrile neutropenia (FN) remains unknown. This study aimed to identify opportunities for blood culture diagnostic stewardship in persistent FN. Methods: This was a retrospective cohort study of patients with hematology/oncology diagnoses and an FN episode lasting >3 days. Generalized estimating equation logistic regression models were used to evaluate risk factors for new bloodstream infection (BSI) after FN day 3. Results: Among 620 patients, the median FN duration was 5 days, with a median of 12 blood culture bottles collected per patient. On FN day 1, 25% of patients had a positive blood culture; on FN days 2–9, <5% of patients per day had a new organism isolated. Among 31 new organisms isolated after FN day 3, 8 (26%) were contaminants. Of 503 patients with ≥1 blood culture collected after FN day 3, 19 (4%) had a new BSI after FN day 3. FN onset in the peri–hematopoietic cell transplant period (from day −7 to day +30) was associated with lower odds of new BSI after FN day 3 (odds ratio, 0.18 [95% confidence interval, .04–.71]; P = .01). Thirty-six patients died within 30 days after FN day 3, including 4 with a new BSI after FN day 3; 1 death was attributable to BSI after FN day 3. Conclusions: Detection of new BSIs after FN day 3 was uncommon, demonstrating the low diagnostic yield of repeat blood cultures after FN day 3. FN episodes in the peri–hematopoietic cell transplant period may be a potential focus for blood culture diagnostic stewardship initiatives.
- 15 May 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (1) , 58-61
You’ve Got a Friend in Me: Curbside Questions Infectious Diseases Clinicians Ask Infectious Diseases Pharmacists
This multicenter study highlights the critical role of infectious diseases (ID) pharmacists in supporting ID consult services, with 89% of 1518 curbside inquiries from ID clinicians resulting in clinical management changes as recommended by the pharmacist. These findings emphasize the necessity of ID pharmacists in optimizing multidisciplinary patient care.
- 15 May 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (1) , 58-61
You’ve Got a Friend in Me: Curbside Questions Infectious Diseases Clinicians Ask Infectious Diseases Pharmacists
This multicenter study highlights the critical role of infectious diseases (ID) pharmacists in supporting ID consult services, with 89% of 1518 curbside inquiries from ID clinicians resulting in clinical management changes as recommended by the pharmacist. These findings emphasize the necessity of ID pharmacists in optimizing multidisciplinary patient care.
- Open Access
- 3 July 2024
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 6 (4) , dlae126
Ceftriaxone-resistant viridans streptococci bacteraemia among patients treated at a large comprehensive cancer care centre: a retrospective eighteen-year study
Viridans streptococci (VS) are opportunistic oral commensals and a common cause of bacteraemia in neutropenic patients. In this retrospective single centre cohort study, we investigated the prevalence of ceftriaxone resistance in VS (CRO-R VS) blood isolates between January 2005 and December 2022 from patients treated at a tertiary care hospital. Blood culture isolates were identified using biochemicals and mass spectrometry. Susceptibility testing was performed by Kirby–Bauer and Epsilometer tests. Demographic data, clinical outcomes and antimicrobial use were assessed through electronic medical record review. Among 791 patients with VS bacteraemia, 31 (4%) had confirmed CRO-R VS bacteraemia over the 18-year period; 20/31 (65%) were patients also treated at the Fred Hutchinson Cancer Center and were the focus of this study. Of these 20 patients, 18 (90%) had a known haematologic malignancy; 14 (70%) had undergone haematopoietic cell transplant (HCT); 18 (90%) were neutropenic at the time of culture. Two (10%) patients died within 30 days of CRO-R VS bacteraemia. All the CRO-R isolates (20/20) were members of the Streptococcus mitis group, 12 were multi-drug resistant; all were susceptible to vancomycin. Most patients received vancomycin once blood cultures were positive for a Gram-positive organism. During the study period, the frequency of VS isolate susceptibility testing increased; however, there was no concomitant increase in the percentage of CRO-R isolates at our facility. These data are important in an era where cefepime monotherapy is often used and reinforces the importance of routine resistance testing among VS bacteraemia.
- 3 July 2024
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 6 (4) , dlae126
Open AccessCeftriaxone-resistant viridans streptococci bacteraemia among patients treated at a large comprehensive cancer care centre: a retrospective eighteen-year study
Viridans streptococci (VS) are opportunistic oral commensals and a common cause of bacteraemia in neutropenic patients. In this retrospective single centre cohort study, we investigated the prevalence of ceftriaxone resistance in VS (CRO-R VS) blood isolates between January 2005 and December 2022 from patients treated at a tertiary care hospital. Blood culture isolates were identified using biochemicals and mass spectrometry. Susceptibility testing was performed by Kirby–Bauer and Epsilometer tests. Demographic data, clinical outcomes and antimicrobial use were assessed through electronic medical record review. Among 791 patients with VS bacteraemia, 31 (4%) had confirmed CRO-R VS bacteraemia over the 18-year period; 20/31 (65%) were patients also treated at the Fred Hutchinson Cancer Center and were the focus of this study. Of these 20 patients, 18 (90%) had a known haematologic malignancy; 14 (70%) had undergone haematopoietic cell transplant (HCT); 18 (90%) were neutropenic at the time of culture. Two (10%) patients died within 30 days of CRO-R VS bacteraemia. All the CRO-R isolates (20/20) were members of the Streptococcus mitis group, 12 were multi-drug resistant; all were susceptible to vancomycin. Most patients received vancomycin once blood cultures were positive for a Gram-positive organism. During the study period, the frequency of VS isolate susceptibility testing increased; however, there was no concomitant increase in the percentage of CRO-R isolates at our facility. These data are important in an era where cefepime monotherapy is often used and reinforces the importance of routine resistance testing among VS bacteraemia.
- Open Access
- 25 April 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (5) , ofae235
Implementation of an Automated Antibiotic Time-out at a Comprehensive Cancer Center
Background: Antimicrobial stewardship programs can optimize antimicrobial use and have been federally mandated in all hospitals. However, best stewardship practices in immunocompromised patients with cancer are not well established. Methods: An antimicrobial time out, in the form of an email, was sent to physicians caring for hospitalized patients reaching 5 days of therapy for targeted antimicrobials (daptomycin, linezolid, tigecycline, vancomycin, imipenem/cilastatin, meropenem) in a comprehensive cancer center. Physicians were to discontinue the antimicrobial if unnecessary or document a rationale for continuation. This is a quasi-experimental, interrupted time series analysis assessing antimicrobial use during the following times: period 1 (before time-out: January 2007-June 2010) and period 2 (after time-out: July 2010-March/2015). The primary antimicrobial consumption metric was mean duration of therapy. Days of therapy per 1000 patient-days were also assessed. Results: Implementation of the time-out was associated with a significant decrease in mean duration of therapy for the following antimicrobials; daptomycin: −0.89 days (95% confidence interval [CI], −1.38 to −.41); linezolid: −0.89 days (95% CI, −1.27 to −.52); meropenem: −0.97 days (95% CI, −1.39 to −.56); tigecycline: −1.41 days (95% CI, −2.19 to −.63); P < .001 for each comparison. Days of therapy/1000 patient-days decreased significantly for meropenem (−43.49; 95% CI, −58.61 to −28.37; P < .001), tigecycline (−35.47; 95% CI, −44.94 to −26.00; P < .001), and daptomycin (−9.47; 95% CI, −15.25 to −3.68; P = .002). Discussion: A passive day 5 time-out was associated with reduction in targeted antibiotic use in a cancer center and could potentially be successfully adopted to several settings and electronic health records.
- 25 April 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (5) , ofae235
Open AccessImplementation of an Automated Antibiotic Time-out at a Comprehensive Cancer Center
Background: Antimicrobial stewardship programs can optimize antimicrobial use and have been federally mandated in all hospitals. However, best stewardship practices in immunocompromised patients with cancer are not well established. Methods: An antimicrobial time out, in the form of an email, was sent to physicians caring for hospitalized patients reaching 5 days of therapy for targeted antimicrobials (daptomycin, linezolid, tigecycline, vancomycin, imipenem/cilastatin, meropenem) in a comprehensive cancer center. Physicians were to discontinue the antimicrobial if unnecessary or document a rationale for continuation. This is a quasi-experimental, interrupted time series analysis assessing antimicrobial use during the following times: period 1 (before time-out: January 2007-June 2010) and period 2 (after time-out: July 2010-March/2015). The primary antimicrobial consumption metric was mean duration of therapy. Days of therapy per 1000 patient-days were also assessed. Results: Implementation of the time-out was associated with a significant decrease in mean duration of therapy for the following antimicrobials; daptomycin: −0.89 days (95% confidence interval [CI], −1.38 to −.41); linezolid: −0.89 days (95% CI, −1.27 to −.52); meropenem: −0.97 days (95% CI, −1.39 to −.56); tigecycline: −1.41 days (95% CI, −2.19 to −.63); P < .001 for each comparison. Days of therapy/1000 patient-days decreased significantly for meropenem (−43.49; 95% CI, −58.61 to −28.37; P < .001), tigecycline (−35.47; 95% CI, −44.94 to −26.00; P < .001), and daptomycin (−9.47; 95% CI, −15.25 to −3.68; P = .002). Discussion: A passive day 5 time-out was associated with reduction in targeted antibiotic use in a cancer center and could potentially be successfully adopted to several settings and electronic health records.
- 18 August 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (S1) , e14129
Antimicrobials in patients with hematologic malignancies and recipients of hematopoietic cell transplantation and other cellular therapies
Background: Appropriate use of antimicrobials for hematologic malignancy, hematopoietic stem cell transplant recipients, and other cellular therapies is vital, with infection causing significant morbidity and mortality in this unique population of immunocompromised hosts. However, often in this population the choice and management of antimicrobial therapy is complex. When selecting an antimicrobial agent, key considerations include the need for dose adjustments due to renal or hepatic impairment, managing drug interactions, the potential for additive drug toxicity among those receiving polypharmacy and therapeutic drug monitoring. Other factors include leveraging pharmacodynamic principles to enable optimization of directed therapy against challenging pathogens, as well as judicious use of antimicrobials to limit drug resistance and adverse drug reactions.Summary: This review summarizes the clinical considerations for commonly used antimicrobials in this setting, including antibacterial, antiviral, and antifungal agents. image
- 18 August 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (S1) , e14129
Antimicrobials in patients with hematologic malignancies and recipients of hematopoietic cell transplantation and other cellular therapies
Background: Appropriate use of antimicrobials for hematologic malignancy, hematopoietic stem cell transplant recipients, and other cellular therapies is vital, with infection causing significant morbidity and mortality in this unique population of immunocompromised hosts. However, often in this population the choice and management of antimicrobial therapy is complex. When selecting an antimicrobial agent, key considerations include the need for dose adjustments due to renal or hepatic impairment, managing drug interactions, the potential for additive drug toxicity among those receiving polypharmacy and therapeutic drug monitoring. Other factors include leveraging pharmacodynamic principles to enable optimization of directed therapy against challenging pathogens, as well as judicious use of antimicrobials to limit drug resistance and adverse drug reactions.Summary: This review summarizes the clinical considerations for commonly used antimicrobials in this setting, including antibacterial, antiviral, and antifungal agents. image
- Open Access
- 24 May 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (8) , 511.e1-511.e10
Voriconazole in Hematopoietic Stem Cell Transplantation and Cellular Therapies: Real-World Usage and Therapeutic Level Attainment at a Major Transplantation Center
- 24 May 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (8) , 511.e1-511.e10
Open AccessVoriconazole in Hematopoietic Stem Cell Transplantation and Cellular Therapies: Real-World Usage and Therapeutic Level Attainment at a Major Transplantation Center